Insulin Aspart 50 biosimilar (Jilin Huisheng Biological)

门冬胰岛素50生物类似药（吉林惠升）

Report date: 2024/01/10 15:13:44

Base Information

Drug NameInsulin Aspart 50 biosimilar (Jilin Huisheng Biological)
Drug Alias Name门冬胰岛素50注射液
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/26
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJilin Huisheng Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJilin Huisheng Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A